Treating primary hepatic carcinoma with transcatheter hepatic arterial chemoembolization combined percutaneous microwave coagulation

Objective To evaluate clinical value of transcatheter hepatic arterial chemoembolization(TACE) combined with percutaneous microwave coagulation therapy(PMCT) in treating primary hepatic carcinoma(PHC).Methods Fourty-eight patients with PHC were equally randomized into two groups of A(treated with TACE and PMCT) and B(treated with TACE).The expressions of T-cell subsets in PHC tissues were detected before and after treatment.The size of tumor was measured by color Doppler sonography periodically.Liver function,AFP and AFP mRNA were examinated at the same times.Results Compared to group B,in group A,the effectiveness rate was higher(88.6% vs.66.7%)(P0.05),the disppearence rate of tumor was higher(95.8% vs.33.3%),the expression level of CD8+ T cells was higher,but that of CD4+ T cells was lower.The survival rates of 6 month,12 month and 18 month of group A were 91.7%,75.0%,37.5%,which were 70.8 %,37.5%,20.8% in group B,respectively.Conclusion The treatment of PHC TACE combined with PMCT is a safe,minimal invasive and effective in the patients with PHC.